| Hematology E-Book: Basic Principles and Practice R Hoffman, EJ Benz, LE Silberstein, H Heslop, J Weitz, ME Salama Elsevier Health Sciences, 2022 | 1813 | 2022 |
| Inducible apoptosis as a safety switch for adoptive cell therapy A Di Stasi, SK Tey, G Dotti, Y Fujita, A Kennedy-Nasser, C Martinez, ... New England Journal of Medicine 365 (18), 1673-1683, 2011 | 1701 | 2011 |
| Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma MA Pule, B Savoldo, GD Myers, C Rossig, HV Russell, G Dotti, MH Huls, ... Nature medicine 14 (11), 1264-1270, 2008 | 1420 | 2008 |
| Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation CM Rooney, CYC Ng, S Loftin, CA Smith, C Li, RA Krance, MK Brenner, ... The Lancet 345 (8941), 9-13, 1995 | 1393 | 1995 |
| Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma CU Louis, B Savoldo, G Dotti, M Pule, E Yvon, GD Myers, C Rossig, ... Blood, The Journal of the American Society of Hematology 118 (23), 6050-6056, 2011 | 1387 | 2011 |
| Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus–induced lymphoma in allogeneic transplant recipients CM Rooney, CA Smith, CYC Ng, SK Loftin, JW Sixbey, Y Gan, ... Blood, The Journal of the American Society of Hematology 92 (5), 1549-1555, 1998 | 1374 | 1998 |
| CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients B Savoldo, CA Ramos, E Liu, MP Mims, MJ Keating, G Carrum, ... The Journal of clinical investigation 121 (5), 1822-1826, 2011 | 1299 | 2011 |
| Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma N Ahmed, VS Brawley, M Hegde, C Robertson, A Ghazi, C Gerken, E Liu, ... Journal of clinical oncology 33 (15), 1688-1696, 2015 | 1102 | 2015 |
| Long–term restoration of immunity against Epstein–Barr virus infection by adoptive transfer of gene–modified virus–specific T lymphocytes HE Heslop, CYC Ng, C Li, CA Smith, SK Loftin, RA Krance, MK Brenner, ... Nature medicine 2 (5), 551-555, 1996 | 1033 | 1996 |
| Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients HE Heslop, KS Slobod, MA Pule, GA Hale, A Rousseau, CA Smith, ... Blood, The Journal of the American Society of Hematology 115 (5), 925-935, 2010 | 942 | 2010 |
| An inducible caspase 9 safety switch for T-cell therapy KC Straathof, MA Pule, P Yotnda, G Dotti, EF Vanin, MK Brenner, ... Blood 105 (11), 4247-4254, 2005 | 852 | 2005 |
| HER2-specific chimeric antigen receptor–modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial N Ahmed, V Brawley, M Hegde, K Bielamowicz, M Kalra, D Landi, ... JAMA oncology 3 (8), 1094-1101, 2017 | 842 | 2017 |
| Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15 Y Xu, M Zhang, CA Ramos, A Durett, E Liu, O Dakhova, H Liu, ... Blood, The Journal of the American Society of Hematology 123 (24), 3750-3759, 2014 | 832 | 2014 |
| Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety V Hoyos, B Savoldo, C Quintarelli, A Mahendravada, M Zhang, J Vera, ... Leukemia 24 (6), 1160-1170, 2010 | 669 | 2010 |
| Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals AM Leen, GD Myers, U Sili, MH Huls, H Weiss, KS Leung, G Carrum, ... Nature medicine 12 (10), 1160-1166, 2006 | 643 | 2006 |
| Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study CRY Cruz, KP Micklethwaite, B Savoldo, CA Ramos, S Lam, S Ku, ... Blood, The Journal of the American Society of Hematology 122 (17), 2965-2973, 2013 | 617 | 2013 |
| Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation AM Leen, CM Bollard, AM Mendizabal, EJ Shpall, P Szabolcs, JH Antin, ... Blood, The Journal of the American Society of Hematology 121 (26), 5113-5123, 2013 | 617 | 2013 |
| A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells MA Pulè, KC Straathof, G Dotti, HE Heslop, CM Rooney, MK Brenner Molecular Therapy 12 (5), 933-941, 2005 | 616 | 2005 |
| T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model A Di Stasi, B De Angelis, CM Rooney, L Zhang, A Mahendravada, ... Blood, The Journal of the American Society of Hematology 113 (25), 6392-6402, 2009 | 608 | 2009 |
| Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins CM Bollard, S Gottschalk, V Torrano, O Diouf, S Ku, Y Hazrat, G Carrum, ... Journal of Clinical Oncology 32 (8), 798-808, 2014 | 558 | 2014 |
Malcolm BrennerProfessor of Medicine, Baylor College of MedicineVerified email at txch.org
